The test is a targeted sequencing assay that detects mutations in the blood of non-small cell lung cancer patients to inform treatment selection.
The institutes will explore the use of Inivata's liquid biopsy platform to analyze ctDNA to measure minimal residual disease in NSCLC patients.
The company's test boasted strong sensitivity and specificity for a range of different alterations in clinical and contrived samples, particularly for low-allele frequencies.
Inivata and Thermo Fisher Scientific will use their liquid biopsy technologies to test plasma samples from Genomics England's 100,000 Genomes Project to assess their quality.
The lung cancer institute will work with Inivata to study the use of ctDNA testing in patients with early lung cancer after surgery.
Results of a new study show that patients guided to targeted therapy based on ctDNA get the same benefits as those who got tissue-based tests in initial clinical trials.
N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.
Inivata has completed the analytical validation of its 35-gene ctDNA test and plans to conduct clinical validation studies from labs in North Carolina and the UK.
Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.
NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.
A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.
In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.